These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23079519)

  • 1. In vivo activity of an azole series of CCR2 antagonists.
    Smethurst CA; Bevan N; Brooks C; Emmons A; Gough PJ; Mookherjee C; Moores K; Peace S; Philp J; Piercy V; Watson SP; Zippoli M
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7252-5. PubMed ID: 23079519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.
    Wang GZ; Haile PA; Daniel T; Belot B; Viet AQ; Goodman KB; Sha D; Dowdell SE; Varga N; Hong X; Chakravorty S; Webb C; Cornejo C; Olzinski A; Bernard R; Evans C; Emmons A; Briand J; Chung CW; Quek R; Lee D; Gough PJ; Sehon CA
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7291-4. PubMed ID: 22047688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a sulfonamide series of CCR2 antagonists.
    Peace S; Philp J; Brooks C; Piercy V; Moores K; Smethurst C; Watson S; Gaines S; Zippoli M; Mookherjee C; Ife R
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3961-4. PubMed ID: 20627722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of novel cyclohexylamide CCR2 antagonists.
    Lanter JC; Markotan TP; Zhang X; Subasinghe N; Kang FA; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Molloy CJ; Sui Z
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7496-501. PubMed ID: 22061641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
    Xue CB; Wang A; Meloni D; Zhang K; Kong L; Feng H; Glenn J; Huang T; Zhang Y; Cao G; Anand R; Zheng C; Xia M; Han Q; Robinson DJ; Storace L; Shao L; Li M; Brodmerkel CM; Covington M; Scherle P; Diamond S; Yeleswaram S; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7473-8. PubMed ID: 21036044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of INT131: a selective PPARĪ³ modulator that enhances insulin sensitivity.
    Taygerly JP; McGee LR; Rubenstein SM; Houze JB; Cushing TD; Li Y; Motani A; Chen JL; Frankmoelle W; Ye G; Learned MR; Jaen J; Miao S; Timmermans PB; Thoolen M; Kearney P; Flygare J; Beckmann H; Weiszmann J; Lindstrom M; Walker N; Liu J; Biermann D; Wang Z; Hagiwara A; Iida T; Aramaki H; Kitao Y; Shinkai H; Furukawa N; Nishiu J; Nakamura M
    Bioorg Med Chem; 2013 Feb; 21(4):979-92. PubMed ID: 23294830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.
    Cai C; Kang FA; Hou C; O'Neill JC; Opas E; McKenney S; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2013 Jan; 23(1):351-4. PubMed ID: 23182090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.
    von Geldern TW; Hoffman DJ; Kester JA; Nellans HN; Dayton BD; Calzadilla SV; Marsh KC; Hernandez L; Chiou W; Dixon DB; Wu-Wong JR; Opgenorth TJ
    J Med Chem; 1996 Feb; 39(4):982-91. PubMed ID: 8632421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists.
    Nirogi RV; Daulatabad AV; Parandhama G; Mohammad S; Sastri KR; Shinde AK; Dubey PK
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4440-3. PubMed ID: 20594839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.
    Kothandaraman S; Donnely KL; Butora G; Jiao R; Pasternak A; Morriello GJ; Goble SD; Zhou C; Mills SG; Maccoss M; Vicario PP; Ayala JM; Demartino JA; Struthers M; Cascieri MA; Yang L
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1830-4. PubMed ID: 19237282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
    Cumming JG; Bower JF; Waterson D; Faull A; Poyser PJ; Turner P; McDermott B; Campbell AD; Hudson J; James M; Winter J; Wood C
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3895-9. PubMed ID: 22608963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.
    Buntinx M; Hermans B; Goossens J; Moechars D; Gilissen RA; Doyon J; Boeckx S; Coesemans E; Van Lommen G; Van Wauwe JP
    J Pharmacol Exp Ther; 2008 Oct; 327(1):1-9. PubMed ID: 18599682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles.
    Walter M; Isensee K; Kottke T; Ligneau X; Camelin JC; Schwartz JC; Stark H
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5883-6. PubMed ID: 20727744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor.
    Doyon J; Coesemans E; Boeckx S; Buntinx M; Hermans B; Van Wauwe JP; Gilissen RA; De Groot AH; Corens D; Van Lommen G
    ChemMedChem; 2008 Apr; 3(4):660-9. PubMed ID: 18188859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
    Zhang X; Hufnagel H; Markotan T; Lanter J; Cai C; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5577-82. PubMed ID: 21783361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrogen-appended N-alkylsulfonamides as inhibitors of gamma-secretase.
    Bergstrom CP; Sloan CP; Wang HH; Parker MF; Smith DW; Zheng M; Hansel SB; Polson CT; Barber LE; Bursuker I; Guss VL; Corsa JA; Barten DM; Felsenstein KM; Roberts SB
    Bioorg Med Chem Lett; 2008 Jan; 18(1):175-8. PubMed ID: 18023581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.
    Mahalingam AK; Wan Y; Murugaiah AM; Wallinder C; Wu X; Plouffe B; Botros M; Nyberg F; Hallberg A; Gallo-Payet N; Alterman M
    Bioorg Med Chem; 2010 Jun; 18(12):4570-90. PubMed ID: 20493713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
    Cherney RJ; Brogan JB; Mo R; Lo YC; Yang G; Miller PB; Scherle PA; Molino BF; Carter PH; Decicco CP
    Bioorg Med Chem Lett; 2009 Feb; 19(3):597-601. PubMed ID: 19131247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.
    Xia M; Hou C; DeMong DE; Pollack SR; Pan M; Brackley JA; Jain N; Gerchak C; Singer M; Malaviya R; Matheis M; Olini G; Cavender D; Wachter M
    J Med Chem; 2007 Nov; 50(23):5561-3. PubMed ID: 17929797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-content analysis of CCR2 antagonists on human primary monocytes.
    Kredel S; Wolff M; Hobbie S; Bieler M; Gierschik P; Heilker R
    J Biomol Screen; 2011 Aug; 16(7):683-93. PubMed ID: 21540351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.